Considering that the pharmacy benefit manager CVS Caremark removed its coverage for Zepbound in July, its likely that more people will consider microdosing to help stretch out those very expensive prescriptions
We combine clinically proven medications with individual counseling on lifestyle, nutrition, diet, and exercise
Generic and biosimilar timeline The pharmaceutical patent landscape suggests that generic and biosimilar versions of current GLP-1 medications will eventually enter the market, though not immediately
According to CMSs website, the program will launch on July 1 and will cease at the end of 2027
Right now, its going through phase 3 clinical trials , which are the final stage before approval
Second, structured surveillance protocols should prioritize the initial treatment month when approximately 46% of NAEs occur, with scheduled follow-ups during this period